| Year |
Citation |
Score |
| 2024 |
Wu M, Wang Y, Wu C, Huang H, Zhou X, Wang J, Xiong S, Dong C. A novel vesicular stomatitis virus armed with IL-2 mimic for oncolytic therapy. Virologica Sinica. PMID 39299564 DOI: 10.1016/j.virs.2024.09.007 |
0.339 |
|
| 2024 |
Wang Q, He M, Liang J, Tan X, Wu Q, Wang J, Li X, Qiao M, Huang Z, Xie Q, Liu Z, Ren H, Wang L, Zhou H, Shao L, et al. Chinese guidelines for integrated diagnosis and treatment of intestinal microecology technologies in tumor application (2024 Edition). Journal of Cancer Research and Therapeutics. 20: 1130-1140. PMID 39206974 DOI: 10.4103/jcrt.jcrt_32_24 |
0.337 |
|
| 2023 |
Wang J, Chen T, Ruszaj DM, Mager DE, Straubinger RM. Integrated PK/PD modeling relates Smoothened inhibitor biomarkers to the heterogeneous intratumor disposition of cetuximab in pancreatic cancer tumor models. Journal of Pharmaceutical Sciences. PMID 37844759 DOI: 10.1016/j.xphs.2023.10.019 |
0.615 |
|
| 2020 |
Greene MK, Chen T, Robinson E, Straubinger NL, Minx C, Chan DKW, Wang J, Burrows JF, Van Schaeybroeck S, Baker JR, Caddick S, Longley DB, Mager DE, Straubinger RM, Chudasama V, et al. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer. PMID 32913288 DOI: 10.1038/S41416-020-01046-6 |
0.556 |
|
| 2019 |
Wang J, Chan DK, Sen A, Ma WW, Straubinger RM. Tumor priming by SMO inhibition enhances antibody delivery and efficacy in a pancreatic ductal adenocarcinoma model. Molecular Cancer Therapeutics. PMID 31363010 DOI: 10.1158/1535-7163.Mct-18-0354 |
0.644 |
|
| 2018 |
Huang ZG, Lv FM, Wang J, Cao SJ, Liu ZP, Liu Y, Lu WY. RGD-modified PEGylated paclitaxel nanocrystals with enhanced stability and tumor-targeting capability. International Journal of Pharmaceutics. PMID 30557679 DOI: 10.1016/j.ijpharm.2018.12.023 |
0.307 |
|
| 2018 |
Chan D, Minx C, Wang J, Sen A, Johnston M, Ma WW, Scott CJ, Straubinger RM. Abstract 3704: Efficacy of DR5-targeted immunoliposomes in pancreatic cancer models primed with SMO inhibitors Cancer Research. 78: 3704-3704. DOI: 10.1158/1538-7445.Am2018-3704 |
0.629 |
|
| 2014 |
Wang J, Qu Y, Pitoniak R, Trueman-Fatallah SA, Hylander BL, Repasky EA, Ma WW, Straubinger RM. Abstract 2691: Smo-targeted sonic hedgehog signaling inhibitor enhances therapeutic antibody deposition and efficacy in a patient-derived pancreatic ductal adenocarcinoma model Cancer Research. 74: 2691-2691. DOI: 10.1158/1538-7445.Am2014-2691 |
0.637 |
|
| Show low-probability matches. |